Clinical Trials Logo
  1. Home
  2. Acute Graft Versus Host Disease
  3. NCT04539470

Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Acute Graft-versus-host Disease Clinical Trial

Official title:
A Phase Ib, Open-Label, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Clinical Trial Summary

This is a Phase Ib, open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of Efmarodocokin Alfa and to make a preliminary assessment of activity of Efmarodocokin Alfa in combination with standard-of-care (SOC) in the prevention of acute graft-versus-host disease (aGVHD) in participants undergoing allogeneic hematopoietic stem cell transplantation (HSCT).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04539470
Study type Interventional
Source Genentech, Inc.
Contact
Status Completed
Phase Phase 1
Start date November 19, 2020
Completion date February 24, 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02241018 - MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD Phase 2/Phase 3
Terminated NCT02245412 - A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease Phase 2
Recruiting NCT02659657 - Prophylaxis Roles of IL-2 Treatment on GVHD After Transplantation Phase 2
Completed NCT03497273 - Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects Phase 1
Completed NCT05825833 - Infliximab Efficacy in Relation to Therapeutic Drug Monitoring and Serum TNFα Levels in Pediatric HSCT
Not yet recruiting NCT06294691 - Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases Phase 3
Not yet recruiting NCT06294678 - Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Phase 3
Recruiting NCT04285424 - FMT for Steroid Resistant Gut Acute GVHD Early Phase 1
Terminated NCT01903473 - Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD) Phase 2
Recruiting NCT02044185 - Clinical Implications of HMGB1 in Patients Treated With Chemotherapy or Hematopoietic Stem Cell Transplantation N/A
Recruiting NCT01765634 - Mesenchymal Stem Cells for Treatment of Refractory Acute Graft-versus-host Disease Phase 2
Terminated NCT00282503 - Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease Phase 3
Recruiting NCT01521039 - Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease
Terminated NCT03721965 - Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects Phase 1/Phase 2
Not yet recruiting NCT04971551 - A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease. Phase 2
Completed NCT02743351 - Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies Phase 1/Phase 2
Active, not recruiting NCT06394895 - Donor Neutrophil Subsets to Predict the Risk of aGVHD
Terminated NCT05673876 - A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD) Phase 1
Recruiting NCT02611180 - Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease